Every few weeks, the public health establishment rolls out the same tired script. A panel of well-meaning academics or institutional advisors issues a report demanding that the government—usually via a national health scheme like the Pharmaceutical Benefits Scheme—step in, foot the bill, and subsidize a newly highlighted drug or class of treatments. The latest headlines breathlessly declare that experts recommend public funding for specific therapeutics covering breast cancer, endometriosis, and gender dysphoria.
The lazy consensus writes itself: corporate greed is blocking access, patients are suffering, and the state must become the universal sugar daddy to make medicine fair.
It is a comforting narrative. It is also completely wrong.
When you demand that the state underwrite the commercial risk of multi-indication therapeutics, you do not create a healthcare utopia. You construct a bureaucratic labyrinth that stifles independent pricing discovery, rewards political lobbying over clinical breakthroughs, and ultimately starves the very pipeline you claim to protect. I have spent two decades watching venture capital and institutional grant systems distort drug development, and the push for blanket state subsidies is the single most efficient way to turn a miracle molecule into a municipal bottleneck.
Let us dismantle the premise of the entire debate.
The Fallacy of the Universal Subsidy
The core misunderstanding driving these expert recommendations is the belief that government funding accelerates access without strings attached. In reality, state-backed reimbursement is a command-and-control mechanism.
When a government agency becomes the primary buyer for a drug used across disparate conditions like oncology, chronic inflammatory disorders, or endocrine treatments, the free market ceases to function. Price discovery vanishes. Instead of value being determined by clinical utility, patient outcomes, and manufacturing scarcity, price is dictated by committee negotiation.
Imagine a scenario where a single pharmaceutical compound shows high efficacy in treating both late-stage breast cancer and severe endometriosis. Under a private market framework, the developer can price-discriminate based on severity, urgency, and R&D recovery timelines for distinct indications.
Inject the government subsidy machine into that equation, and the system grinds to a halt. Bureaucrats demand uniform pricing models for conditions that share nothing in common except a molecular target. The result? Pharmaceutical firms stop pursuing multi-indication research because the compliance overhead and price caps mandated by state payers make the business case unviable.
You wanted affordable access. You actually engineered a disincentive for versatility.
The Misdiagnosis of Market Failure
The public narrative insists that high drug prices represent a market failure. This is amateur hour economics. High drug prices at launch represent the deferred cost of extraordinary failure.
For every drug that makes it past regulatory approval for breast cancer or complex endocrine conditions, nine thousand compounds die in preclinical trials. Investors front billions of dollars expecting that the few winners will generate the returns necessary to fund the next generation of high-risk research.
When experts argue that the government should bypass this risk structure by subsidizing production or forcing price controls, they are treating biotechnology like a utility company. Medicine is not water treatment. It is an exercise in applied molecular probability.
If you cap the upside through aggressive state subsidization and mandatory discounting, capital flees the sector. Venture firms stop funding early-stage oncology and endocrinology startups and pour their money into SaaS or consumer tech, where margins are not subject to a health minister's political calculus.
The downside of my contrarian approach is brutal and transparent: without government intervention, some patients will experience delayed access to high-cost therapeutics. That is an undeniable tragedy. But the alternative—a state-managed rationing system where drugs are perpetually backlogged, supply chains are controlled by civil servants, and innovation flatlines—leads to a far worse outcome for everyone who hasn't even been diagnosed yet.
Redefining the Question
The media loves to frame this as an access issue. Should the government pay for X?
It is the wrong question. The right question is: Why is the cost of bringing a molecule to market so artificially inflated that only a government subsidy or a monopoly pricing model can clear the hurdle?
The answer lies in regulatory bloat and clinical trial bureaucracy. The Food and Drug Administration and its international counterparts require clinical trial designs that cost upwards of a billion dollars per drug, much of it spent satisfying redundant administrative hurdles rather than proving basic safety and efficacy.
If we want cheaper drugs for breast cancer, endometriosis, and complex gender-affirming care, the solution is not to hand the checkbook to the state. The solution is to slash regulatory friction, decentralize clinical trials, and allow adaptive trial designs that lower the cost of capital generation.
When you lower the cost of creation, you eliminate the need for the state to act as a savior.
The True Cost of State Reliance
Let us look at how this plays out in practice. When a government program lists a drug under its subsidized schedule, it creates a monopsony. The state becomes the sole buyer with the leverage to crush suppliers.
Proponents cheer this as a victory for the taxpayer. It is a short-term illusion.
Once a government agency holds monopsony power, pharmaceutical developers pivot their R&D budgets away from high-stigma, politically sensitive, or complex multi-indication drugs. They chase low-hanging fruit—me-too drugs for lifestyle conditions with guaranteed, high-volume, low-risk state payouts.
Endometriosis has been medically underserved for decades precisely because it sits at the intersection of chronic pain, hormonal complexity, and historical medical neglect. Slapping a government subsidy on a repurposed oncology drug does nothing to fix the underlying lack of basic research into endometrial tissue pathology. It simply creates a queue for an existing product while starving the pipeline of novel ones.
Gender dysphoria treatments suffer from a similar pathology. The discourse is so politically toxic that relying on state funding committees to rationally evaluate clinical data is a fool's errand. Funding decisions become hostages to electoral cycles. A change in government brings a change in reimbursement guidelines, leaving patients stranded not by market forces, but by political whim.
What Actually Works
If you want a resilient healthcare ecosystem, you must decouple patient access from government benevolence.
- Voucher Systems and Direct-to-Consumer Innovation: Move away from central bulk-buying schemes. Implement direct patient stipends or portable health savings mechanisms that allow individuals to choose their treatments without a bureaucrat deciding if their specific manifestation of endometriosis or cancer meets an arbitrary reimbursement threshold.
- Open-Source Pharmacology: Accelerate the off-patent repurposing pipeline by removing intellectual property monopolies on generic compounds, allowing independent compounding pharmacies to manufacture and distribute multi-indication drugs at cost.
- Regulatory Streamlining: Cut clinical trial approval timelines in half by accepting real-world evidence and digital biomarker tracking, slashing the upfront capital required to bring a molecule to market.
Stop waiting for the state to rescue patients from a crisis the state helped create through regulatory overreach and price distortion.
The next time an expert panel releases a report demanding government funding for the flavor-of-the-month therapeutic, look past the compassionate rhetoric. They are not advocating for patients. They are advocating for a system of state control that destroys the very engine of human ingenuity required to cure disease in the first place.
/saur-energy/media/post_attachments/2023/02/green_funding.jpg)
